Aptuit has increased its global capacity for API manufacture, opening of a 1600L/1000L reactor stream at its API facility in Oxford, UK and increasing throughput for 400L reactors at its fully integrated, former large Pharma R&D center of excellence in Verona, Italy. Aptuit’s strategy aims to allow increased throughput of integrated development programs, as well as deliver standalone API at 40-120 kg batch scale for early to mid-stage clinical trials. 
 
Dr. Goldman chief executive officer, Aptuit LLC, said, “Customer demand for our high quality, integrated, fully inclusive candidate-to-IND solutions has increased over 300% on an annual basis. There is a gap in the market for high quality API at this scale, and Aptuit is delighted to serve this need. Our company differentiates in API by quality, best-in-class science, and delivery of complex chemistry solutions. Our ability to combine this with drug product and analytical services results in unique integrated offerings in both CMC and complete IND enabling solutions. The innovative approach has created strong demand amongst customers, and stimulated our plan to re-invest to increase our capacity in API.”